— Late-Breaking Oral Presentations on AR101 Phase 3 PALISADE Results in Peanut-Allergic Children and Adults and on European Study of Psychosocial Impact of Peanut Allergy —

Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it will present data on peanut allergy at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018, taking place May 26–30 in Munich.

Late-breaking oral and poster presentations will report additional data from Aimmune's pivotal PALISADE Phase 3 clinical trial, which evaluated the efficacy and safety of AR101, Aimmune's investigational biologic oral immunotherapy for desensitization of patients with peanut allergy. Other presentations will report on the variability of terminology used in oral immunotherapy in the United States and on the Allergy to Peanuts ImPacting Emotions and Life (APPEAL) study conducted with European food allergy advocacy groups on the psychosocial burden of peanut allergy.

Data from AR101 Program / Phase 3 PALISADE Study

Late-Breaking Abstract: #1874
Title: Efficacy and Safety of AR101 in Peanut Allergic Patients Aged 4–55: Results from an International Phase 3, Randomised, Double-Blind, Placebo-Controlled Trial (PALISADE)
Presenter: George du Toit, M.B., B.Ch.
Session: Oral Abstract Session 20: Management of Food Allergy
Date: Monday, May 28
Time: 15:45 – 17:15, Central European Time
Location: Hall 13b, Messe München

Late-Breaking Abstract: #1672
Title: Immune Responses in 496 Patients Aged 4–17 Years with Peanut Allergy Treated with Oral Immunotherapy Using AR101: Results from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial (PALISADE)
Presenter: Kirsten Beyer, M.D.
Session: Late-Breaking Poster Discussion Session 1: Trendsetting in Immunotherapy Vaccines
Date: Sunday, May 27
Time: 13:30 – 15:00 Central European Time
Location: Poster Discussion Zone 2, Messe München

Data from European APPEAL Study of Psychosocial Impact of Peanut Allergy

Data on Variability in Oral Immunotherapy Terminology

Aimmune will also host a company-sponsored satellite symposium, Immunotherapy for Food Allergy — Evolution or Revolution? (SAT 13), on Monday, May 28, at 17:45 – 19:15 Central European Time in Hall C, Messe München.

About Aimmune Therapeutics

This press release concerns a product that is under clinical investigation and that has not yet been approved for marketing by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). It is currently limited to investigational use, and no representation is made as to its safety or effectiveness for the purposes for which it is being investigated.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180515005692/en/